Mock FDA Inspection
Full dress-rehearsal inspections that put your site, documents, and team through realistic FDA scrutiny before the real visit.
Audit & Inspection Readiness Services
See What an FDA Investigator Would See — First
Independent audits and mock inspections that surface and close gaps before they become Form 483 observations.
cGMP & Quality Audits
Independent review of quality systems, manufacturing controls, and data integrity to find regulatory-readiness gaps early.
Inspection Readiness Playbooks
Practical FDA, EMA, and global-regulator readiness plans, front-room/back-room prep, and SME coaching.
500+Regulatory inspections supported, with responses that hold under FDA scrutiny
200+New product launches delivered without regulatory disruption
13Global regulatory bodies navigated, including FDA, EMA, and WWHA
CAPARemediation planning support for quality-system correction and inspection readiness
2025-2026 Enforcement Signals
Current FDA Pressure Is Concentrated in Quality Systems, Validation, and Response Discipline
The U.S. and Puerto Rico report points to domestic enforcement, quality-unit failures, process validation gaps, water and sterility risk, OOS investigations, and new AI-documentation scrutiny as launch campaign context.
U.S. and Puerto Rico Actions Reviewed
The campaign should speak to domestic manufacturers facing active Form 483, Warning Letter, adulteration, and repeat-observation pressure.
FY2025 Inspection-Based Warning Letters Were Domestic
Messaging should stay focused on U.S. and Puerto Rico operators that need senior, confidential support.
Quality-Unit Failure Citations
Recurring themes include quality-unit authority, written procedures, process validation, component testing, OOS investigations, and CAPA depth.
cGMP Documentation Scrutiny Is Expanding
The report flags AI-generated compliance documents without qualified human quality-unit review as a new enforcement frontier.
Proactive Quality & Regulatory Compliance
Preventive Inspection Readiness Playbooks
David's meeting notes frame LaSalle's broader offer around identifying gaps, improving the QMS, and helping quality teams stay compliant, efficient, and continuously improving.
Quality Audits
Independent review of quality systems, manufacturing controls, and regulatory-readiness gaps before observations pile up.
Inspection Readiness Playbooks
Practical FDA, EMA, and global-regulator readiness plans for teams preparing proactively or facing a near-term inspection.
QMS + QA/QC Support
Quality assurance, quality control, and quality-unit support for CAPA, deviations, material testing, batch release, and QMS performance.
QC Lean Transformation + Lean Labs
Quality-control laboratory improvement focused on throughput, testing discipline, and lean lab operations.
In Good Company
Trusted by Life Sciences Companies Where Failure Isn’t an Option
We’ve supported organizations facing the same regulatory pressure you are, including global manufacturers and complex multi-site environments.
Global manufacturers
Multi-site environments
Quality leaders
Regulatory teams
Inspection pressure
Why LaSalle
Why Quality & Regulatory Leaders Bring in LaSalle
Senior operators, regulatory realism, and agency-ready responses built to hold up under follow-up inspection.
Senior Operators, Not Advisors
You work directly with leaders who have managed FDA inspections from inside manufacturing sites, not junior teams learning on your timeline.
Built for Regulatory Reality
We don’t just respond to observations. We identify what caused them and stabilize the system behind them, so findings don’t repeat.
Designed to Hold Up Under Inspection
Responses are structured to withstand follow-up inspections, not just close to the letter.
Enterprise Experience Without Bureaucracy
We operate at the level of global consulting firms, without delays, layers, or generic playbooks.
Global Regulatory Coverage
We navigate FDA, EMA, MHRA, and other global regulatory bodies for organizations managing compliance across multiple sites and regions.
Start the Conversation
If You’re Holding an FDA 483 or Warning Letter — Don’t Delay
Early response decisions determine whether issues are contained or expanded. Use the form to request a confidential consultation with a senior practitioner and choose a time between 9am and 4pm Eastern.